A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

(2017) Yazhou Li et al.   JOURNAL OF ALZHEIMERS DISEASE

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

(2015) Daniel I Swerdlow et al.   LANCET

The support of human genetic evidence for approved drug indications

(2015) Matthew R Nelson et al.   NATURE GENETICS

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility

(2015) Jennifer Wessel et al.   Nature Communications

Cardiovascular Actions of Incretin-Based Therapies

(2014) John R. Ussher et al.   CIRCULATION RESEARCH

A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes

(2014) L. J. Schmidt et al.   DIABETES OBESITY & METABOLISM

Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin

(2014) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)

(2014) Chang Yu Pan et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)

(2014) Julio Rosenstock et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

(2014) Mike A Nalls et al.   NATURE GENETICS

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer

(2014) Brian M Wolpin et al.   NATURE GENETICS

Loss-of-function mutations in SLC30A8 protect against type 2 diabetes

(2014) Jason Flannick et al.   NATURE GENETICS

Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

(2013) Bo Ahrén et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin

(2013) Matthew C. Riddle et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

(2013) Matthew C. Riddle et al.   DIABETES CARE

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)

(2013) M. Pinget et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

(2013) G. B. Bolli et al.   DIABETIC MEDICINE

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

(2013) M E J Lean et al.   INTERNATIONAL JOURNAL OF OBESITY

Exenatide and the treatment of patients with Parkinson’s disease

(2013) Iciar Aviles-Olmos et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of heart rate–associated loci and their effects on cardiac conduction and rhythm disorders

(2013) Marcel den Hoed et al.   NATURE GENETICS

Validating therapeutic targets through human genetics

(2013) Robert M. Plenge et al.   NATURE REVIEWS DRUG DISCOVERY

Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo-Controlled Trial

(2013) Giuseppe Derosa et al.   PHARMACOTHERAPY

Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

(2013) Michael Grimm et al.   POSTGRADUATE MEDICINE

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia

(2013) Martin Lorenz et al.   REGULATORY PEPTIDES

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

The Effect of Glucagon-Like Peptide-1 Receptor Agonist Therapy on Body Mass Index in Adolescents With Severe Obesity

(2013) Aaron S. Kelly et al.   JAMA Pediatrics

Exenatide as a Novel Weight Loss Modality in Patients Without Diabetes

(2012) Jessica L Moreno et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

(2012) T. Forst et al.   DIABETIC MEDICINE

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes

(2012) G. Derosa et al.   DIABETIC MEDICINE

Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies

(2012) N. G. Forouhi et al.   DIABETOLOGIA

What makes UK Biobank special?

(2012) Rory Collins   LANCET

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

(2012) Adam P. Gregory et al.   NATURE

Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes

(2012)   NATURE GENETICS

Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways

(2012) Robert A Scott et al.   NATURE GENETICS

A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance

(2012) Alisa K Manning et al.   NATURE GENETICS

The effect of glucagon-like peptide 1 on cardiovascular risk

(2012) Jacob Sivertsen et al.   Nature Reviews Cardiology

Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes

(2012) J. A. Tennessen et al.   SCIENCE

An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People

(2012) M. R. Nelson et al.   SCIENCE

Recent Explosive Human Population Growth Has Resulted in an Excess of Rare Genetic Variants

(2012) A. Keinan et al.   SCIENCE

Blood Pressure Loci Identified with a Gene-Centric Array

(2011) Toby Johnson et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

(2011) J. Dushay et al.   DIABETES CARE

Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study

(2011)   DIABETOLOGIA

Polymorphism and Ligand Dependent Changes in Human Glucagon-Like Peptide-1 Receptor (GLP-1R) Function: Allosteric Rescue of Loss of Function Mutation

(2011) C. Koole et al.   MOLECULAR PHARMACOLOGY

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Association between birth weight and visceral fat in adults

(2010) Emanuella De Lucia Rolfe et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

(2010) Caroline M. Apovian et al.   AMERICAN JOURNAL OF MEDICINE

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

(2010) Anne Gill et al.   Cardiovascular Diabetology

Effects of Exenatide Plus Rosiglitazone on  -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

(2010) R. A. DeFronzo et al.   DIABETES CARE

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

(2010) J. Liutkus et al.   DIABETES OBESITY & METABOLISM

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

(2010) R. E. Ratner et al.   DIABETIC MEDICINE

Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance

(2010) Julio E. Ayala et al.   ENDOCRINOLOGY

Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies

(2010) Themistocles L. Assimes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge

(2010) Richa Saxena et al.   NATURE GENETICS

Deep resequencing reveals excess rare recent variants consistent with explosive population growth

(2010) Alex Coventry et al.   Nature Communications

The ADDITION-Cambridge trial protocol: a cluster – randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients

(2009) Justin B Echouffo-Tcheugui et al.   BMC PUBLIC HEALTH

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

(2009) Takashi KADOWAKI et al.   ENDOCRINE JOURNAL

Pharmacological Characterization of Human Incretin Receptor Missense Variants

(2009) J.-P. Fortin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome

(2008) Mathieu Firmann et al.   BMC Cardiovascular Disorders

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

(2008) Y. Seino et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

(2008) Yan Gao et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome

(2008) Karen Elkind-Hirsch et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

(2008) Timothy J. Ley et al.   NATURE

Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides

(2008) Jaspal S Kooner et al.   NATURE GENETICS

Exenatide and Rare Adverse Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease

(2008) Jeppe Zacho et al.   NEW ENGLAND JOURNAL OF MEDICINE